Summary Immunodeprived mice survived a high, otherwise lethal dose of cyclophosphamide (Cy) provided they had been "primed" with a low dose (50mg kg-1) of 
It has been known for some time that low dose cyclophosphamide (Cy) pretreatment or "priming" 4 days before high dose administration improves mouse survival in otherwise normal C57B 1 mice, (Millar & McElwain, 1978; Millar et al., 1980) . It was also demonstrated that priming does not alter the efficacy of the large challenge dose in terms of the curability of the Lewis lung carcinoma or tumour growth delay of the FS6 fibrosarcoma both of which are syngeneic in C57B1 mice (Millar & McElwain, 1978; Millar et al., 1980) . The mechanism underlying these observations is not understood.
The object of this study was first to establish whether immunodeprived mice bearing human oat cell tumour xenografts would withstand high dose Cy therapy better when they had been primed 4 days earlier with low dose Cy (50mg kg-1), and then to see if the anti-tumour efficacy of the high dose was altered by priming. 
Materials and methods

Mice
Female CBA/lac mice were immunosuppressed by thymectomy at 4 weeks of age, followed 4 weeks later by 9 Gy whole body irradiation, (Steel et al., 1978) .
Tumours
The 2 human oat cell xenograft lines used in these experiments, HX69 and HX72, (HX being the acronym for human xenograft), were originally established from material obtained by surgical biopsy. The tumours used in these experiments were in early passage (6) (7) (8) (9) (10) (11) (12) (13) (14) and had been shown by histology and chromosome analysis to have retained their human characteristics, (Shorthouse et al., 1980) . At the start of each experiment, tumour fragments measuring about 1-2mm were bilaterally implanted s.c. into the flanks of these 8-10 week old mice, as described elsewhere, (Evans et al., 1982 (1981) .
Chemotherapeutic response The growth rates of individual tumours were measured by comparing the volume at time t (Vt) with its volume at the beginning of the experiment (Vo). The value Vt/Vo was calculated for each tumour at each sampling time and a mean and s.e. calculated for each group. Where a death occurred or a tumour completely regressed, that animal or tumour was excluded from any further calculation. Growth delay is defined here as the time taken for the average tumour volume to recover to the treatment volume. Where a high percentage of the mice died or a group of tumours failed to regrow sufficiently, the results are expressed simply as deaths or complete remissions.
Statistics
In order to establish the significance of growth delay differences, individual times taken for tumours to regrow to treatment volume were ranked and the non-parameteric Mann-Whitney Utest used to obtain a P value. Where insufficient tumours regrew to perform this analysis satisfactorily, Student's t-test was used to compare the mean volume ratios at the time of greatest tumour regression. Tumour responses HX69 after 200mgkg-1 Cy It can be seen ( Figure  2 ) that this dose of Cy produced a growth delay of -34 days in this tumour line. In the animals that were primed a growth delay of 45 days was achieved. In addition there were 3/5 deaths and no complete remissions in the control group and only 1 death out of 5 and 2/8 complete remissions in the primed group. At the day of greatest regression, the volume ratio of the primed group was significantly smaller than that of the control group (P<0.002).
Results
Survival
HX69 after 300mgkg-1 Cy The effect of this dose of Cy on animal survival is presented in Table II which shows that 16/17 of the unprimed controls died. Of the 28 tumours originally present 14 were in complete remission at the time of death, the median day of death was 42 and the median day of complete remission was 26. Figure 3 shows that all the animals in the unprimed group were dead by Day 46. In the primed group there were 2 survivors out of 9 at 60 days. The growth delay in both groups were similar, being -32 days for the primed group and 27 days for the controls. HX72 after 200mg kg-cyclophosphamide To ensure that the slightly increased growth delays seen in the primed animals were not due to the fact that they received slightly greater total doses of Cy in this experiment a stat dose of 250mg kg-was given to the controls and compared with the response in the group that received 50mg kg-1 prime 4 days before 200mg kg-1. To bias the experiment against ourselves the stat dose was given to the controls at the time of the prime, the challenge dose in the primed group being given 4 days later, (Figure 4) . Here, the growth delay of the primed group appeared to be slightly shorter than that of the control group when both are measured from the day of challenge (23 vs. 30 days), but the growth delays were not significantly different when they were measured from Day 3, i.e. when treatment began, (27 vs. 30 days).
Discussion
The first part of this study dealt with the ability of a small dose of Cy to prime against a large dose of the drug in immunodeprived mice. The survival data show that Cy pretreatment confers the same type of protection against the toxic effects of high dose Cy in immunodeprived mice as it does in normal mice (Millar & McElwain 1978) . This is perhaps unexpected as in the course of immunodeprivation the mice received 9 Gy total body irradiation (TBI) which would have been lethal to the mice but for a priming dose of cytosine arabinoside (200mg kg-1) given 2 days before the TBI (Millar et al., 1978a; Steel et al., 1978) . These animals were primed twice therefore, first with cytosine arabionoside before irradiation and then about 4 weeks later with low dose Cy before high dose Cy and in both instances the normal tissue-damaging effect of the the challange dose was reduced. This demonstrates that mice are capable of being primed twice with different drugs against widely different cytotoxic agents. This finding may have some bearing on clinical research where normal tissue damage limits the multi-modal therapy under investigation.
It must be stressed in the case of Cy that although the Cy prime reduced the normal tissue toxicity of the challenge dose it did not completely abolish toxic deaths, particularly in situations where the tumour itself caused fatalities or weakened the animals (Figure 3) . Also, although cell synchrony may play a part in the priming of cytosine arabinoside on irradiation , the mechanism by which Cy primes on itself remains unclear. The simplest explanation, namely that the priming dose alters the pharmacokinetics of the challenge drug, is unlikely for 2 reasons. First, direct measurement of the clearance of labelled Cy was unaltered by priming and second, the antitumour efficacy of the challenge dose of drug was not impaired by priming. If priming caused the challenge dose to be more rapidly metabolised, thus reducing normal tissue damage, this would have been reflected in less effective tumour control. However, there was no evidence of this.
Indeed, within any one xenograft line (and in every experiment to larger or lesser degree) priming reduced normal tissue toxicity whilst maintaining anti-tumour efficacy. In other words the therapeutic gain seen in putatively immunocompetent tumourbearing mice (Millar & McElwain 1978 , Millar et al., 1978b was produced in human xenograft bearing animals too. It is possible, bearing in mind the correlation between the xenograft chemosensitivity and parent tumour (Shorthouse et al., 1980) , that some oat cell tumours in patients may also be sensitive to high dose Cy. If Cy priming similarly reduces normal tissue toxicity in man then it may be possible to administer larger doses than would normally be tolerated, to patients with oat cell carcinoma, or more conventional doses with greater safety and improved therapeutic index.
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